Emerging Trends to Reshape the Global Short Bowel Syndrome Market: Advancements In GLP-2 Analog Therapies For Short Bowel Syndrome And Intestinal Failure as a Key Influencer

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Short Bowel Syndrome Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market designated for short bowel syndrome is experiencing swift expansion, escalating from its 2024 valuation of $2.69 billion to project a value of $3.08 billion for 2025, reflecting a compound annual growth rate of 14.6% throughout this timeframe. This substantial upward trajectory observed during the historical period stems from several contributing factors, namely the heightened incidence of digestive system ailments, greater spending on medical care coupled with broader insurance accessibility, enhancements in how patients recovering from SBS surgery are managed post-operation, a rise in the occurrence of conditions like Crohn's disease alongside other gastrointestinal issues, and advancements noted in both the composition and methods of administering parenteral nutrition.

Short Bowel Syndrome Market Size Forecast: What's the Projected Valuation by 2029?
Anticipated for the short bowel syndrome market is a period of swift expansion over the forthcoming years, projecting an increase to $5.29 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.4%. This upward trajectory throughout the projection timeframe is fueled by several key factors: the escalating incidence of short bowel syndrome (SBS), wider acceptance of both parenteral and enteral nutrition treatments, intensified clinical investigation and pharmaceutical advancement, augmented spending on healthcare services, and greater public knowledge coupled with earlier identification of SBS. Key shifts characterizing this forecast era encompass progress within intestinal rehabilitation methods, refinement of small intestine transplantation procedures, greater utilization of telehealth for overseeing SBS cases, innovations in equipment for enteral feeding, and the incorporation of artificial intelligence to aid in formulating SBS treatment strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

What Are the Drivers Transforming the Short Bowel Syndrome Market?
The rising incidence of ailments affecting the digestive system is anticipated to fuel expansion within the short bowel syndrome market moving ahead, given that these widespread gastrointestinal disorders, which encompass maladies of the stomach, intestines, liver, and pancreas often resulting in compromised digestion and nutrient uptake, are predominantly spurred by poor eating patterns that upset gut equilibrium and encourage inflammatory responses, and these conditions can ultimately precipitate short bowel syndrome through the required surgical resection of diseased bowel portions, diminishing the overall absorptive surface area; for example, data from the IBD Clinical and Research Centre in Canada indicated that in September 2023, over 320,000 Canadians, representing a prevalence rate of 825 per 100,000, were affected by inflammatory bowel disease (IBD), with projections showing this number climbing to 470,000 Canadians, or 1.1 percent of the population, by 2035 due to an expected annual prevalence increase of 2.44 percent, underscoring how the growing burden of gastrointestinal diseases contributes directly to market growth for short bowel syndrome.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

What Long-Term Trends Will Define the Future of the Short Bowel Syndrome Market?
Leading organizations within the short bowel syndrome marketplace are channeling efforts toward pioneering breakthroughs in medical science, specifically focusing on therapies for intestinal failure, aiming to deliver sophisticated treatment modalities that elevate recovery metrics for individuals suffering from gastrointestinal ailments. Intestinal failure constitutes a severe state wherein the small intestine lacks the capability to absorb sufficient nourishment, hydration, and essential electrolytes necessary for sustaining adequate bodily function. As an illustration, during May of 2024, Ironwood Pharmaceuticals, Inc., a healthcare entity situated in the United States, publicized fresh evidence stemming from investigations assessing apraglutide in adult participants afflicted with short bowel syndrome complicated by intestinal failure (SBS-IF). This agent, recognized as a subsequent generation GLP-2 analog, exhibited promise for augmenting intestinal uptake and lessening the dependency on parenteral therapies. These results emphasize the drug's effectiveness, overall safety profile, and advantages when administered over extended periods, thereby highlighting Ironwood's dedication to forging novel treatments for conditions affecting the gastrointestinal tract.

Which Segments in the Short Bowel Syndrome Market Offer the Most Profit Potential?
The short bowel syndromemarket covered in this report is segmented -

1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine
2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis
3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

Subsegments:
1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues
2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies
3) By Glutamine: Oral Glutamine; Intravenous Glutamine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

Which Firms Dominate the Short Bowel Syndrome Market by Market Share and Revenue in 2025?
Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.

Which Regions Offer the Highest Growth Potential in the Short Bowel Syndrome Market?
North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.